Recro Pharma Inc (NASDAQ:REPH) Short Interest Down 15.5% in January

Recro Pharma Inc (NASDAQ:REPH) was the recipient of a significant drop in short interest in the month of January. As of January 31st, there was short interest totalling 1,090,000 shares, a drop of 15.5% from the January 15th total of 1,290,000 shares. Approximately 5.7% of the shares of the company are short sold. Based on an average trading volume of 341,900 shares, the short-interest ratio is currently 3.2 days.

Shares of REPH stock traded down $0.30 on Friday, reaching $18.48. The company’s stock had a trading volume of 242,518 shares, compared to its average volume of 279,033. Recro Pharma has a 12-month low of $5.53 and a 12-month high of $19.21. The company has a market capitalization of $405.05 million, a P/E ratio of -7.90 and a beta of -0.31. The stock’s 50 day simple moving average is $17.00 and its 200-day simple moving average is $14.29.

REPH has been the subject of a number of analyst reports. ValuEngine lowered Recro Pharma from a “buy” rating to a “hold” rating in a report on Tuesday, December 3rd. Zacks Investment Research upgraded Recro Pharma from a “hold” rating to a “buy” rating and set a $15.00 price objective on the stock in a research report on Wednesday, October 30th. BidaskClub upgraded Recro Pharma from a “hold” rating to a “buy” rating in a research report on Wednesday, February 5th. Finally, Stephens lowered their price objective on Recro Pharma from $23.00 to $19.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 26th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Recro Pharma has an average rating of “Buy” and a consensus target price of $15.38.

Hedge funds have recently modified their holdings of the stock. Royal Bank of Canada purchased a new stake in shares of Recro Pharma in the second quarter worth $198,000. State Street Corp raised its position in shares of Recro Pharma by 31.2% in the third quarter. State Street Corp now owns 394,904 shares of the specialty pharmaceutical company’s stock worth $4,376,000 after buying an additional 93,855 shares in the last quarter. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Recro Pharma in the fourth quarter worth $858,000. California State Teachers Retirement System raised its position in shares of Recro Pharma by 2.3% in the third quarter. California State Teachers Retirement System now owns 30,178 shares of the specialty pharmaceutical company’s stock worth $334,000 after buying an additional 688 shares in the last quarter. Finally, BlackRock Inc. raised its position in shares of Recro Pharma by 14.9% in the second quarter. BlackRock Inc. now owns 1,292,173 shares of the specialty pharmaceutical company’s stock worth $13,142,000 after buying an additional 167,346 shares in the last quarter. Institutional investors own 60.12% of the company’s stock.

About Recro Pharma

Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.

Further Reading: Neutral Rating

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.